Compound Evidence File
#EC-2026-0889
ANPP (4-anilino-N-phenethylpiperidine) CAS 21409-26-7
Filed under Raw Materials. The bureau holds 121 laboratory returns for this compound from 41 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
41 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 4 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 4 | 10.0 | 9.9 | 10.0 | 8 May 2026 | 4 Jul 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 4 | 10.0 | 10.0 | 10.0 | 7 Dec 2025 | 13 Jun 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 3 | 10.0 | 9.9 | 10.0 | 2 Jun 2026 | 22 Jun 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 3 | 10.0 | 10.0 | 10.0 | 8 Apr 2026 | 6 Jun 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 3 | 10.0 | 9.9 | 10.0 | 21 Jul 2026 | 17 Aug 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 3 | 10.0 | 9.9 | 10.0 | 20 Dec 2025 | 6 Jul 2026 |
| SinoPepCASE #VI-2026-0387 | A | 3 | 10.0 | 9.9 | 10.0 | 12 Dec 2025 | 20 Jul 2026 |
| AsymchemCASE #VI-2026-0091 | A | 3 | 10.0 | 9.9 | 10.0 | 2 Mar 2026 | 17 May 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 2 | 10.0 | 10.0 | 10.0 | 14 May 2026 | 21 Jun 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 2 | 10.0 | 10.0 | 10.0 | 23 May 2026 | 2 Jul 2026 |
| Risynth BioCASE #VI-2026-0672 | X | 1 | 10.0 | 10.0 | 10.0 | 14 Jan 2025 | 14 Jan 2025 |
| HomopeptideCASE #VI-2026-0760 | A | 7 | 9.9 | 9.9 | 10.0 | 21 May 2026 | 21 May 2026 |
| BachemCASE #VI-2026-0314 | A | 4 | 9.9 | 9.9 | 10.0 | 4 Mar 2026 | 23 Jun 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 4 | 9.9 | 9.9 | 10.0 | 8 Nov 2025 | 15 Feb 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 4 | 9.9 | 9.9 | 10.0 | 16 Apr 2026 | 27 Jun 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 4 | 9.9 | 9.9 | 10.0 | 7 Jan 2026 | 25 Jun 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 4 | 9.9 | 9.9 | 10.0 | 19 Jan 2026 | 10 Jun 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 4 | 9.9 | 9.9 | 10.0 | 8 Apr 2026 | 17 Jul 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 9.9 | 9.9 | 10.0 | 20 May 2026 | 10 Jun 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 2 | 9.9 | 9.9 | 10.0 | 23 Jan 2026 | 28 Jan 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 2 | 9.9 | 9.9 | 10.0 | 23 Dec 2025 | 1 May 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 2 | 9.9 | 9.9 | 10.0 | 7 Nov 2025 | 5 Jun 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 2 | 9.9 | 9.9 | 10.0 | 28 Mar 2026 | 19 Aug 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 7 | 8.8 | 7.9 | 9.9 | 21 May 2026 | 21 May 2026 |
| Bfflist AMOCASE #VI-2026-0678 | X | 4 | 8.8 | 7.4 | 10.0 | 2 Jul 2025 | 26 Jan 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 7 | 8.6 | 7.6 | 9.2 | 24 May 2026 | 24 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 6 | 8.6 | 7.3 | 9.4 | 24 May 2026 | 24 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 3 | 8.3 | 7.6 | 8.7 | 21 May 2026 | 21 May 2026 |
| The Naughty NeedleCASE #VI-2026-0432 | X | 1 | 8.1 | 8.1 | 8.1 | 3 Jul 2025 | 3 Jul 2025 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 5 | 7.8 | 6.6 | 8.7 | 24 May 2026 | 24 May 2026 |
| Aavant ResearchCASE #VI-2026-0831 | X | 1 | 7.4 | 7.4 | 7.4 | 13 Jun 2025 | 13 Jun 2025 |
| YB PeptideCASE #VI-2026-0813 | X | 1 | 7.3 | 7.3 | 7.3 | 2 Apr 2025 | 2 Apr 2025 |
| PeptiLab ResearchCASE #VI-2026-0267 | X | 1 | 7.0 | 7.0 | 7.0 | 13 Feb 2025 | 13 Feb 2025 |
| Mix PeptidesCASE #VI-2026-0699 | X | 1 | 6.9 | 6.9 | 6.9 | 9 Jun 2025 | 9 Jun 2025 |
| Yongkang Nuoao Trading CoCASE #VI-2026-0646 | X | 1 | 6.9 | 6.9 | 6.9 | 13 Jun 2025 | 13 Jun 2025 |
| Regenerative ResearchCASE #VI-2026-0349 | X | 1 | 6.3 | 6.3 | 6.3 | 8 Jul 2025 | 8 Jul 2025 |
| Loti LabsCASE #VI-2026-0171 | X | 3 | 4.4 | 3.7 | 5.2 | 11 Jun 2025 | 21 May 2026 |
| PurePeptidesCASE #VI-2026-0234 | X | 1 | 2.7 | 2.7 | 2.7 | 3 Jul 2025 | 3 Jul 2025 |
| Peptide ArkCASE #VI-2026-0350 | X | 1 | 0.0 | 0.0 | 0.0 | 13 Jun 2025 | 13 Jun 2025 |
| Lejian Biotech PeptideCASE #VI-2026-0746 | X | 1 | 0.0 | 0.0 | 0.0 | 13 Jun 2025 | 13 Jun 2025 |
Open any subject to view the batch-level evidence for ANPP (4-anilino-N-phenethylpiperidine) CAS 21409-26-7 alone.